CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 74 enrolled
Drug / intervention
MK-0893 +3 moredrug
Likely dose
MK-0893 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02004886
NCT02004886Phase 2Completed
CompareCT.gov

A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Panel Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Patients With Type 2 Diabetes Mellitus

Merck Sharp & Dohme LLC·interventional·Posted Dec 9, 2013·Updated Sep 5, 2018

In Brief

A Phase 2 clinical trial evaluating MK-0893, Metformin, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 74 participants.

Detailed Summary

This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus. The primary hypothesis is that MK-0893 will reduce 24-hour weighted mean glucose (WMG) significantly more than placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 9, 2013
Enrollment StartAug 11, 2006
Primary CompletionFeb 7, 2007
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 12.6 years ago

Interventions

MK-0893drug

10 mg and 100 mg tablets

Metformindrug

500 mg metformin tablets

Placebodrug

Placebo tablets matching MK-0893

Placebodrug

Placebo tablets matching metformin